Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine

References

• Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology68(5), 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 2nd Edition. Cephalalgia24(Suppl. 1), 9–160 (2004).
   PubMedGoogle Scholar
• Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia27(5), 394–402 (2007).
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch. Neurol.59(7), 1084–1088 (2002).
   PubMed Web of Science ®Google Scholar
• Hamel E. Current concepts of migraine pathophysiology. Can. J. Clin. Pharmacol.6(Suppl. A), 9A–14A (1999).
   PubMedGoogle Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N. Engl. J. Med.346(4), 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology10, 107–111 (1960).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain120(Pt 12), 2171–2177 (1997).
   PubMed Web of Science ®Google Scholar
• Burstein R, Jakubowski M, Levy D. Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain115, 21–28 (2005).
   PubMed Web of Science ®Google Scholar
• Schuh-Hofer S, Richter M, Geworski L et al. Increased serotonin transporter availability in the brainstem of migraineurs. J. Neurol.254(6), 789–796 (2007).
   PubMedGoogle Scholar
• Tepper SJ. Tailoring management strategies for the patient with menstrual migraine: focus on prevention and treatment. Headache46(Suppl. 2), S61–S68 (2006).
   Google Scholar
• Freitag FG, Cady R, DiSerio F et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache41(4), 391–398 (2001).
   PubMed Web of Science ®Google Scholar
• Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur. Neurol.47(2), 99–107 (2002).
   PubMed Web of Science ®Google Scholar
• Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur. Neurol.49(1), 20–29 (2003).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet346(8980), 923–926 (1995).
   PubMed Web of Science ®Google Scholar
• The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur. Neurol.32(3), 177–184 (1992).
   PubMed Web of Science ®Google Scholar
• Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur. Neurol.47(2), 88–98 (2002).
   PubMed Web of Science ®Google Scholar
• Frova® Tablets (frovatriptan succinate), prescribing information. Endo Pharmaceuticals Inc., Chadds Ford, PA, USA (2007).
   Google Scholar
• Comer MB. Pharmacology of the selective 5-HT1B/1D agonist frovatriptan. Headache42(Suppl. 2), S47–S53 (2002).
   PubMed Web of Science ®Google Scholar
• Buchan P, Keywood C, Wade A, Ward C. Clinical pharmacokinetics of frovatriptan. Headache42(Suppl. 2), S54–S62 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein J. Frovatriptan: a review. Expert Opin. Pharmacother.4(1), 83–93 (2003).
   PubMed Web of Science ®Google Scholar
• Buchan P, Wade A, Ward C, Oliver SD, Stewart AJ, Freestone S. Frovatriptan: a review of drug–drug interactions. Headache42(Suppl. 2), S63–S73 (2002).
   PubMed Web of Science ®Google Scholar
• Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache42(Suppl. 2), S84–S92 (2002).
   PubMed Web of Science ®Google Scholar
• Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache43(4), 376–388 (2003).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Finlayson G, Rapoport AM et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache47(4), 519–530 (2007).
   PubMed Web of Science ®Google Scholar
• Cady R, Martin V, Mauskop A et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache46(6), 914–924 (2006).
   PubMed Web of Science ®Google Scholar
• Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol.55(1), 27–36 (2004).
   PubMed Web of Science ®Google Scholar
• Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr. Med. Res. Opin.20(9), 1465–1472 (2004).
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Tepper SJ, Sheftell FD, Kung E, Bigal ME. Which triptan for which patient? Neurol. Sci.27(Suppl. 2), S123–S129 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22(8), 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache42(Suppl. 2), S93–S99 (2002).
   Web of Science ®Google Scholar
• Vanguard Medica Ltd. New drug application 21-006. 8.8-Integrated summary of safety. Guildford, Surrey, UK (2001).
   Google Scholar
• Lugardon S, Roussel H, Sciortino V, Montastruc JL, Lapeyre-Mestre M. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database. Eur. J. Clin. Pharmacol.63(8), 801–807 (2007).
   PubMedGoogle Scholar
• Elkind AH, Satin LZ, Nila A, Keywood C. Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache44(5), 403–410 (2004).
   PubMed Web of Science ®Google Scholar
• Pasqual J, Mateos V, Roig C, Sanchez del Rio M, Jimenez D. Marketed oral triptans in the acute treatment of migraine: a systematic review of efficacy and tolerability. Headache47(8), 1152–1168 (2007).
   PubMedGoogle Scholar
• MacGregor EA. Menstruation, sex hormones, and migraine. Neurol. Clin.15(1), 125–141 (1997).
   PubMed Web of Science ®Google Scholar
• Couturier EGM, Bomhof MAM, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia23(4), 302–308 (2003).
   PubMed Web of Science ®Google Scholar
• Dzoljic E, Sipetic S, Vlajinac H et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache42(3), 185–193 (2002).
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache33(7), 385–389 (1993).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: a pilot study. Cephalalgia10(6), 305–310 (1990).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey – Phase III. Curr. Med. Res. Opin.20(7), 1143–1150 (2004).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology63(2), 351–353 (2004).
   PubMed Web of Science ®Google Scholar
• Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia12(4), 221–228 (1992).
   PubMed Web of Science ®Google Scholar
• Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology45(6), 1076–1082 (1995).
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp G. Migraine with aura and reproductive life events: a case control study. Cephalalgia20(8), 701–707 (2000).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Igarashi H, Wilkinson M. Headaches and hormones: subjective versus objective assessment. Headache Quarterly8, 126–136 (1997).
   Web of Science ®Google Scholar
• Loder E. Migraine and menstruation. J. Soc. Obstet. Gynaecol. Can.22(7), 512–517 (2000).
   Google Scholar
• Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis – part I. Headache46(1), 3–23 (2006).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, MacGregor EA, Davies PTG. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache, 3rd edition. British Association for the Study of Headache (2007).
   Google Scholar
• Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol. Sci.27(Suppl. 2), S193–S197 (2006).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J. Headache Pain6(2), 81–87 (2005).
   PubMedGoogle Scholar
• Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet. Gynecol.86(6), 911–916 (1995).
   PubMed Web of Science ®Google Scholar
• Gross M, Barrie M, Bates D, Dowson A, Elrington G. The efficacy of sumatriptan in menstrual migraine. Eur. J. Neurol.2, 144–145 (1995).
   Google Scholar
• Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache44(2), 120–130 (2004).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Keywood C. Frovatriptan is effective in menstrually associated migraine. Cephalalgia20, 345 (2000).
   Google Scholar
• Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur. J. Neurol.12(10), 774–781 (2005).
   PubMed Web of Science ®Google Scholar
• Massiou H, Pitei D, Poole P, Sikes C. Efficacy of eletriptan for the treatment of migraine in women with menstrually associated migraine, and in women on contraceptives or hormone replacement therapy: meta-analyses of randomized clinical trials. Cephalalgia20, 435 (2000).
   Google Scholar
• Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet. Gynecol.102(4), 835–842 (2003).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Armellino JJ, Hoffman HD et al. Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies. Clin. Ther.21(3), 475–491 (1999).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet. Gynecol.96(2), 237–242 (2000).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Massiou H, McCarroll KA, Lines CR. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache42(9), 917–923 (2002).
   PubMed Web of Science ®Google Scholar
• Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet. Gynecol.82(5), 769–772 (1993).
   PubMed Web of Science ®Google Scholar
• Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia116(4), 264–269 (9996).
   Google Scholar
• Martin VT, Wernke S, Mandell K et al. Defining the relationship between ovarian hormones and migraine headache. Headache45(9), 1190–1201 (2005).
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Allais G et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia24(9), 707–716 (2004).
   PubMed Web of Science ®Google Scholar
• Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA295(15), 1824–1830 (2006).
   PubMed Web of Science ®Google Scholar
• Chan WY. Prostaglandins and nonsteroidal antiinflammatory drugs in dysmenorrhea. Annu. Rev. Pharmacol. Toxicol.2, 131–149 (1983).
   Google Scholar
• Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol. Scand.73(5), 490–492 (1986).
   PubMed Web of Science ®Google Scholar
• Gøtzsche P. Non-steroidal anti-inflammatory drugs. BMJ3, 1058–1061 (2000).
   Google Scholar
• Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology22(4), 355–365 (1972).
   PubMed Web of Science ®Google Scholar
• de Lignieres B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. Br. Med. J. (Clin. Res. Ed.)293(6561), 1540 (1986).
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol. Endocrinol.2(2), 113–120 (1988).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology67(12), 2154–2158 (2006).
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V. Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine. Cephalalgia13(Suppl. 13), 244 (1993).
   Google Scholar
• Smite MG, van der Meer YG, Pfeil JP, Rijnierse JJ, Vos AJ. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache34(2), 103–106 (1994).
   PubMedGoogle Scholar
• Pradalier A, Vincent D, Beaulieu P, Baudesson G, Launey J-M. Correlation between estradiol plasma level and therapeutic effect on menstrual migraine. In: New Advances in Headache Research. Rose F (Ed.). Smith-Gordon, London, UK, 129–132 (1994).
   Google Scholar
• Somerville BW. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology25(3), 239–244 (1975).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology67(12), 2159–2163 (2006).
   PubMed Web of Science ®Google Scholar
• Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology51(1), 307–309 (1998).
   PubMed Web of Science ®Google Scholar
• Newman L, Mannix LK, Landy S et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache41(3), 248–256 (2001).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology63(2), 261–269 (2004).
   PubMed Web of Science ®Google Scholar
• Tuchman M, Hee A, Emeribe U. Oral zolmitriptan 2.5 mg demonstrates high efficacy and good tolerability in the prophylaxis treatment of menstrual migraine headaches. Headache45, 771–772 (2005).
   Google Scholar
• Mannix LK, Savani N, Landy S et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache47(7), 1037–1049 (2007).
   PubMed Web of Science ®Google Scholar
• Brandes JL, MacGregor A, Silberstein S, Tobin J, Shaw B. Prevention of difficult-to-treat menstrual migraine using a 6-day regimen of frovatriptan: a second double-blind, randomized, placebo-controlled trial. Headache47(5), 789–790 (2007).
   Google Scholar
• Guidotti M, Mauri M, Barrila C, Guidotti F, Belloni C. Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J. Headache Pain8(5), 283–288 (2007).
   PubMedGoogle Scholar
• Wade A, Warrington S, Whale H, Pawsey S, Gammaitoni A. Pharmacokinetics and tolerability in healthy subjects of 6-day frovatriptan dosing regimen used for the short-term prevention of menstrual migraine. Headache46(5), 844 (2006).
   Google Scholar
• Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 a-ethinylestradiol. Drug Metab. Dispos.32(11), 1209–1212 (2004).
   PubMed Web of Science ®Google Scholar
• MacGregor A, Pawsey S, Campbell J, Tobin J, Gammaitoni A. Use of frovatriptan for the short-term prevention of pure menstrual and menstrually-related migraine headaches: results of a 12-month, open-label safety and tolerability trial. Headache46(5), 844 (2006).
   Google Scholar
• Endo Pharmaceuticals and Vernalis receive action letter from FDA on FROVA® Supplemental New Drug Application. Chadds Ford, PA, USA (2007).
   Google Scholar
• Moschiano F, Allais G, Grazzi L et al. Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol. Sci.26(Suppl. 2), S162–S166 (2005).
   PubMed Web of Science ®Google Scholar
• Brandes J, Smith T, Diamond M, Ames M. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache47(6), 886–894 (2007).
   PubMed Web of Science ®Google Scholar
• Kruit MC, van Buchem MA, Hofman PA et al. Migraine as a risk factor for subclinical brain lesions. JAMA291(4), 427–434 (2004).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Frith A, Ellis J, Aspinall L. Predicting menstrual migraine with a home-use fertility monitor. Neurology64(3), 561–563 (2005).
   PubMed Web of Science ®Google Scholar
• Bussone G, Tullo V, d’Onofrio F et al. Frovatriptan for the prevention of postdural puncture headache. Cephalalgia27(7), 809–813 (2007).
   PubMed Web of Science ®Google Scholar